T-Knife has used its proprietary human TCR transgenic mouse platform to discover and develop a portfolio of TCR-T programs to treat patients with solid tumors. Specifically, the company will use the financing to begin a phase I/II clinical study of TK-8001, a TCR-T cell therapy for melanoma-associated antigen 1 (MAGE-A1) positive solid tumors in the fourth quarter of this year, it said.

The series B funding round was led by Fidelity Management and Research, with participation from LSP, Qatar Investment Authority, Casdin Capital, Sixty Degree Capital, and CaaS Capital.

Blocking some T cells may unleash full power of immune system against cancer
Researchers have identified a way to restrict regulatory T-cell activity in tumor cells, which in turn can unleash other immune cells to attack tumors...

Cellular programming spurs next-generation cell therapies
Cellular reprogramming of ex vivo cells may offer improvements on first-generation adoptive cell therapies, which have experienced limited clinical success...

Machine learning helps scientists map the mammalian immune system
The use of advanced machine-learning software has led to the identification of hundreds of new genes that likely affect the working immune system, according...

Algorithm expands what scientists can uncover from individual cells
A new software tool can help researchers further utilize single-cell RNA sequencing data to learn more about individual cells by incorporating biologically...

CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in...